CancerDrs

Leukemia clinical trials in South Carolina

18 actively recruiting leukemia trials at 17 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…

Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding r…

Sponsor: Syndax Pharmaceuticals
NCT ID: NCT07211958
Sites in South Carolina:
  • Clinical Trial Site — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …

Sponsor: Grifols Therapeutics LLC
NCT ID: NCT05645107
Sites in South Carolina:
  • GC2202 Study Site 110 — Rockville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
  • Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
  • Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in South Carolina:
  • Prisma Health — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • McLeod Regional Medical Center — Florence, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
View on ClinicalTrials.gov →
Recruiting Network

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated i…

Sponsor: Children's Oncology Group
NCT ID: NCT00736749
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
  • Greenville Cancer Treatment Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Network

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear …

Sponsor: Children's Oncology Group
NCT ID: NCT05702645
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Network

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hyd…

Sponsor: Children's Oncology Group
NCT ID: NCT01790152
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in South Carolina:
  • Massive Bio SYNERGY-AI site — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • McLeod Health — Florence, South Carolina
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09